Epigenetics Market is expected to value at USD 22.05 billion in 2025, exhibiting a CAGR of 19.7% during the forecast period of 2018 to 2025. Rapid surge in the product demand is credited to the ever-growing geriatric population and prevalence of chronic diseases. Globally, the epigenetics market is predicted to generate massive revenue over the forecast period, providing numerous opportunities for industry participants to invest in research and development of epigenetics services.
The
identification of severity among patients suffering from chronic diseases and
successful execution of disease management are other major factors driving the
growth of the genetic testing services domain. High-end demand for latest
technologies in healthcare sector and collective research and development
(R&D) activities in the area of genetics is anticipated to foster industry
growth as well.
Request Sample Copy of This Market Research @
https://www.millioninsights.com/industry-reports/epigenetics-market-size/request-sample
Several
diagnostic and testing organization have launched innovative products including
antibodies specific for identification of modifications and advanced kits for
simple and efficient detection of biomarkers. Furthermore, development of
therapeutic drugs by healthcare providers is anticipated to work in favor of
the epigenetics market. Introduction of pipeline drugs and rising approval rate
from local and international authorities is estimated to augment epigenetics
industry growth over the coming years.
Rising
approval rate for therapeutic drugs and epigenetics services is the key
industry trend over the past few years. For example, Eli Lilly and Co., global
pharmaceutical company, has unveiled its product line of advanced therapeutic
drugs Ramucirumab (Cyramza), which is recently approved by FDA. Shifting focus
towards the epigenetics services by pharmaceutical companies for detecting of
methylation markers during cancer treatment is expected to favor epigenetics
industry growth. Epigenomics AG has developed Epi proLung BL Reflex Assay that
allows simple diagnosis for lung cancer.
Browse Full Research Report @
https://www.millioninsights.com/industry-reports/epigenetics-market-size
Epigenetics
services allows understanding of phenotype changes, which involves alterations
in the DNA sequence. Epigenetics testing is performed on various blood sample
taken during different time period in person’s life. The fast paced
technological advancement in epigenetics testing and sequencing methodologies,
has led to the vast expansion of epigenetics testing in preventive healthcare
management.
The
key players are Illumina, Inc., Abcam, Inc., Diagenode S.A., Thermo Fisher Scientific
Group, Merck & Co., Inc., Zymo Research Corp., Qiagen, Inc., CellCentric
Ltd., Chroma Therapeutics Ltd., Eisai Co., Ltd., Novartis International AG,
Oncolys Biopharma Inc., Syndax Pharmaceuticals, Inc., Valirx Plc, and
Sigma-Aldrich Corp.
Comments
Post a Comment